Grant: Engage Grants Program
University of Alberta
$25,000.00
Ultrasound technology platform for biomedical applications
FY 2011-12
Summary
Average human life-span has increased substantially; however, organ and tissue failure remain major threats to
our overall health. Repairing or replacing whole or portions of tissue (i.e., heart, bone, cartilage, blood vessels,
bladder, skin etc.) has become vital to quality of life and sustainable healthcare. Regenerative medicine is often
used synonymously with tissue engineering to develop stem cell treatments to produce replacement tissues
compatible with the patient. In addition to tissue failure, cancers such as lymphoma, leukemia and myeloma,
pose a major threat to human health. High-dose therapy with stem-cell transplantation plays a key role in the
treatment of these cancers. Stem cells extracted from the umbilical cord or from a patient's own body provide a
renewable source of replacement cells and tissue without complications of immune-rejection. However, the
number of stem cells, as well as maintenance of their viability and self-renewal potential, have traditionally
encountered shortfalls, limiting the applications for clinical transplantation. Our lab has successful developed
low-intensity pulsed ultrasound techniques to increase proliferation of stem-cells by up to 100%.
STEMCELL Technologies Inc. is a world renowned Canadian biotechnology company providing reagents for
stem cell research worldwide. In this proposal, we seek to team up with the researchers at STEMCELL
Technologies Inc. to customize our ultrasound device for industrial application. Our ultrasound device can add
value to the current products of STEMCELL Technologies Inc. and further strengthen their leading position in
the global stem-cell market. This NSERC support will enable a Canadian biotechnology company to access
our invention from the University of Alberta and foster technological competiveness in the global marketplace.
Program
Engage Grants Program
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
418773-2011
Name nom
Chen, Jie
Department département
Electrical and Computer Engineering
Organization id
9
Institution établissement
University of Alberta
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2011
Competition year année de concours
2011
Award amount
25000
Program id
EGP
Program nane en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1555
Committee name en
Prairie Internal Decision Committee
Committee name fr
Comité de décision interne pour les Prairies
Area of application code
500
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Manufacturing processes and products
Area of application fr
Procédés et produits industriels
Research subject code
2524
Research subject group en
Electrical and electronic engineering
Research subject group fr
Génie électrique et électronique
Research subject en
Ultrasonic/ferroelectric devices and applications
Research subject fr
Applications et dispositifs ultrasoniques et ferroélectriques
Partie
1
Nb partie
1
Application title
Ultrasound technology platform for biomedical applications
Keyword
NSERC
Application summary
Average human life-span has increased substantially; however, organ and tissue failure remain major threats to
our overall health. Repairing or replacing whole or portions of tissue (i.e., heart, bone, cartilage, blood vessels,
bladder, skin etc.) has become vital to quality of life and sustainable healthcare. Regenerative medicine is often
used synonymously with tissue engineering to develop stem cell treatments to produce replacement tissues
compatible with the patient. In addition to tissue failure, cancers such as lymphoma, leukemia and myeloma,
pose a major threat to human health. High-dose therapy with stem-cell transplantation plays a key role in the
treatment of these cancers. Stem cells extracted from the umbilical cord or from a patient's own body provide a
renewable source of replacement cells and tissue without complications of immune-rejection. However, the
number of stem cells, as well as maintenance of their viability and self-renewal potential, have traditionally
encountered shortfalls, limiting the applications for clinical transplantation. Our lab has successful developed
low-intensity pulsed ultrasound techniques to increase proliferation of stem-cells by up to 100%.
STEMCELL Technologies Inc. is a world renowned Canadian biotechnology company providing reagents for
stem cell research worldwide. In this proposal, we seek to team up with the researchers at STEMCELL
Technologies Inc. to customize our ultrasound device for industrial application. Our ultrasound device can add
value to the current products of STEMCELL Technologies Inc. and further strengthen their leading position in
the global stem-cell market. This NSERC support will enable a Canadian biotechnology company to access
our invention from the University of Alberta and foster technological competiveness in the global marketplace.